Zevra Therapeutics (ZVRA) News Today $9.30 -0.06 (-0.64%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$9.51 +0.21 (+2.20%) As of 06:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)August 28 at 7:30 AM | globenewswire.comZevra Therapeutics, Inc. $ZVRA Holdings Boosted by Stonepine Capital Management LLCAugust 26 at 7:38 AM | marketbeat.comZevra Therapeutics to Participate at Upcoming Investor Conferences in SeptemberAugust 26 at 7:30 AM | globenewswire.comZacks Research Downgrades Zevra Therapeutics (NASDAQ:ZVRA) to HoldAugust 22, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Sees Strong Trading Volume Following Insider Buying ActivityAugust 22, 2025 | americanbankingnews.comZevra Therapeutics rumor highlighted in Betaville blogAugust 21, 2025 | msn.comZevra Therapeutics gains amid takeover speculationAugust 21, 2025 | msn.comZevra Therapeutics (NASDAQ:ZVRA) Director John Bode Buys 5,000 SharesAugust 21, 2025 | insidertrades.comTourmaline Bio (NASDAQ:TRML) versus Zevra Therapeutics (NASDAQ:ZVRA) Head to Head ReviewAugust 20, 2025 | americanbankingnews.comZevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 4.4% - Should You Buy?August 17, 2025 | marketbeat.comCantor Fitzgerald Brokers Lower Earnings Estimates for ZVRAAugust 17, 2025 | marketbeat.comEquities Analysts Offer Predictions for ZVRA Q3 EarningsAugust 17, 2025 | marketbeat.comQ3 EPS Forecast for Zevra Therapeutics Increased by AnalystAugust 17, 2025 | marketbeat.comHC Wainwright Has Bearish Estimate for ZVRA FY2027 EarningsAugust 16, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Shares Gap Down on Analyst DowngradeAugust 15, 2025 | marketbeat.comJMP Securities Lowers Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $18.00August 15, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Releases Quarterly Earnings Results, Misses Estimates By $0.71 EPSAugust 14, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) is Altium Capital Management LLC's Largest PositionAugust 14, 2025 | marketbeat.comZevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial StabilityAugust 14, 2025 | tipranks.comZevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed.August 13, 2025 | msn.comZevra Therapeutics: Zevra Reports Second Quarter 2025 Financial Results and Corporate UpdateAugust 13, 2025 | finanznachrichten.deZevra Therapeutics falls as significant earnings miss overshadows revenue beatAugust 13, 2025 | investing.comZevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comZevra Reports Second Quarter 2025 Financial Results and Corporate UpdateAugust 12, 2025 | globenewswire.comThose who invested in Zevra Therapeutics (NASDAQ:ZVRA) three years ago are up 102%August 11, 2025 | finance.yahoo.comZevra Therapeutics Q2 2025 Earnings PreviewAugust 11, 2025 | msn.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by BrokeragesAugust 10, 2025 | marketbeat.comZevra Therapeutics (ZVRA) to Release Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comZevra Therapeutics Announces Details for Q2 2025 Financial Results CallAugust 4, 2025 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest UpdateAugust 4, 2025 | marketbeat.comWhat is William Blair's Estimate for ZVRA Q3 Earnings?August 1, 2025 | marketbeat.comWhat is William Blair's Estimate for ZVRA FY2025 Earnings?July 31, 2025 | marketbeat.comZevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type CJuly 28, 2025 | globenewswire.comReadystate Asset Management LP Purchases 616,370 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)July 23, 2025 | marketbeat.comAIGH Capital Management LLC Has $10.77 Million Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)July 22, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Downgraded to Buy Rating by Wall Street ZenJuly 20, 2025 | marketbeat.comZevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)July 18, 2025 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Acquired by Mystic Asset Management Inc.July 17, 2025 | marketbeat.comZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics ...July 16, 2025 | finanznachrichten.deZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and MetabolismJuly 16, 2025 | globenewswire.comZevra Therapeutics (NASDAQ:ZVRA) Reaches New 12-Month High - Time to Buy?July 16, 2025 | marketbeat.comQ2 EPS Forecast for Zevra Therapeutics Raised by AnalystJuly 16, 2025 | marketbeat.comWall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should KnowJuly 15, 2025 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Buy" from AnalystsJuly 15, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Outlook for ZVRA EarningsJuly 14, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Upgraded to Strong-Buy at Wall Street ZenJuly 12, 2025 | marketbeat.comZevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation ConferenceJuly 11, 2025 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Sold by Stratos Wealth Partners LTD.July 11, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $29.00 at Cantor FitzgeraldJuly 10, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Reaches New 1-Year High - Here's What HappenedJuly 10, 2025 | marketbeat.com Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZVRA Media Mentions By Week ZVRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZVRA News Sentiment▼0.801.03▲Average Medical News Sentiment ZVRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZVRA Articles This Week▼54▲ZVRA Articles Average Week Get the Latest News and Ratings for ZVRA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Zevra Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ImmunityBio News Ocular Therapeutix News Disc Medicine News Belite Bio News Recursion Pharmaceuticals News CG Oncology News ANI Pharmaceuticals News Sarepta Therapeutics News Mesoblast News Adaptive Biotechnologies News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZVRA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access